• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Clinical Trials

Ocular Therapeutix launches Phase III trial for eye plug

March 19, 2014 By drugdelivery

Ocular Therapeutix launches Phase III trial for eye plug

Bedford, mass.-based Ocular Therapeutix launched Phase III human clinical studies of its drug-releasing optical plug in patients undergoing cataract surgery.

Filed Under: Drug-Device Combinations Tagged With: Clinical Trials, Ocular Therapeutix Inc

Covidien launches 2 trials to support its Stellarex drug-device combo

July 17, 2013 By drugdelivery

Covidien launched 2 trials to support its Stellarex drug-device combo

Covidien (NYSE:COV) kicked off 2 new clinical trials this week to support a global evaluation of its Stellarex drug-coated angioplasty balloon.

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Clinical Trials, Covidien, Peripheral Artery Disease

pSivida launches Phase III study of its micro-sized eye implant

July 5, 2013 By drugdelivery

pSivida launches Phase III of its drug/device combo for vision loss r

pSivida (NSDQ:PSDV) started recruiting patients in a Phase III U.S. trial for its eyelash-sized drug/device combination, an implant designed to treat ocular swelling that can lead to blindness.

Filed Under: Drug-Device Combinations Tagged With: Alimera Sciences, Clinical Trials, pSivida Corp.

Ocular Therapeutix closes enrollment in Phase II study of tear duct plug

June 4, 2013 By drugdelivery

OcularTherapeutix

Ocular Therapeutix wrapped up patient enrollment for a Phase II trial evaluating the company’s OTX-DP tear duct plug, the company announced this week.

Filed Under: Drug-Device Combinations Tagged With: Clinical Trials, Ocular Therapeutix Inc

Delcath's Chemosat gives terminal cancer patients several more months of disease-free life

September 26, 2011 By drugdelivery

Delcath Chemosat

Delcath Systems Inc.’s (NSDQ:DCTH) Chemosat organ-targeting chemotherapy system extended the lives of terminal eye cancer patients by several months without disease progression, researchers said.

Melanoma of the eye often spreads to the liver, generally killing a patient in 1 to 2 months, according to a press release. Patients who received targeted treatment to saturate the liver lived an average of 8.1 months, compared to 1.6 months for patients receiving the best alternative care.

Filed Under: Drug-Device Combinations, Research & Development Tagged With: Clinical Trials, Delcath Systems Inc.

Cancer therapy device maker Delcath drops hard on inconclusive trial results

September 6, 2011 By drugdelivery

Delcath

Delcath Systems Inc. (NSDQ:DCTH) saw share prices drop 11 percent on news that its flagship cancer therapy device presented inconclusive results in treatment of colorectal cancer.

Sixteen patients with very late stage colorectal cancer participated in Delcath’s phase II study of its Chemosat focused chemotherapy delivery system, which uses a series of tubes to aim chemotherapy drugs at a specific organ and then filter the blood to remove the toxins before returning it to the body.

Filed Under: Drug-Device Combinations, Research & Development Tagged With: Clinical Trials, Delcath Systems Inc.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS